

Spotlight on Texas

The V Foundation funds all types of research across all cancer types, including adult and pediatric cancers, common and rare cancers, from the laboratory to clinics, and from prevention and detection through treatment and recurrence.

The V Foundation solicits competitive research proposals from the 73 National Cancer Institute Designated Cancer Centers and other exceptional institutions across North America.

There are four NCI-Designated Cancer Centers in Texas:

- Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine in Houston
- Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center in Dallas
- Mays Cancer Center at UT Health San Antonio, UT Health Science Center in San Antonio
- The University of Texas MD Anderson Cancer Center in Houston

Our Impact on Cancer Research in Texas

We've funded

85 grants totaling over \$30 million.

V Foundation funded researchers in Texas, over their careers, have:

Received

**500+ grants and
\$1.9 billion in funding.**

Produced

**over 13,000
publications.**

Worked on

**156 clinical
trials.**

V Foundation Funded Researchers – Proven Positive Impact

- **Meenakshi Hegde, M.D., MBBS**, is a 2019 Translational Grantee at the Baylor College of Medicine and Texas Children's Hospital.
- Dr. Hegde's research dives into how immunotherapy can be used to treat children and adolescents with sarcoma, a rare type of cancer that develops in the body's connective tissues (ex: bone, muscle, nerves).
- Dr. Hegde recently published exciting results from her V-funded research which supports a phase 1 clinical trial for high-risk sarcoma patients. Dr. Hegde's novel treatment approach engineers immune cells to effectively find and destroy the cancer by targeting a certain protein in the cancer cells.
- The results of the study were very encouraging. The treatment was safe and of the 13 patients participating in the trial, more than half showed some clinical benefit.
- Overall, this research supports a potential safe, new treatment option for sarcoma patients.



Meenakshi Hegde, MBBS,
2019 Translational Grantee